Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 8/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3563156 | 0.91 | CCR3 (0.42) | CCR3KMT2ATP53MAPTMEN1 | |
| SCHEMBL3552561 | 0.90 | KMT2A (0.42) | CCR3KMT2ATP53MAPTMEN1 | |
| SCHEMBL3566882 | 0.90 | CCR3 (0.42) | CCR3KMT2ATP53MAPTMEN1 | |
| SCHEMBL3564358 | 0.88 | HTR2A (0.55) | CCR3POLBHTR2ALMNAALDH1A1 | |
| SCHEMBL3568175 | 0.87 | L3MBTL1 (0.43) | CCR3TP53MAPTPOLBHTR2A | |
| SCHEMBL3561910 | 0.87 | HTR2A (0.51) | CCR3KMT2AMEN1HTR2ALMNA | |
| SCHEMBL3565549 | 0.86 | HTR2A (0.49) | KMT2AMAPTMEN1POLBHTR2A | |
| SCHEMBL3566781 | 0.86 | DPP4 (0.41) | CCR3HTR2ALMNAKDM4EALDH1A1 | |
| SCHEMBL3564913 | 0.86 | HTR2A (0.55) | CCR3TP53POLBHTR2ALMNA | |
| SCHEMBL3565139 | 0.85 | L3MBTL1 (0.59) | POLBLMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7750161-B2 | Pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-07-06 | — | — | US | claimed |
| EP-1670470-B1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-04-08 | — | — | EP | claimed |
| US-20070043081-A1 | Novel pyridine derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2007-02-22 | — | — | US | claimed |
| EP-1670470-B1 | PYRIDINE DERIVATIVES AND USE THEREOF AS UROTENSIN II ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043081-A1 | Novel pyridine derivatives | P2RY4, P2RX6, P2RX4 | CCR3 2602/4885KMT2A 3265/4885TP53 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.